Review: The frequent need for three or more drugs to treat essential hypertension. What evidence for optimal combinations?

Abstract

Treatment of high blood pressure (BP) reduces the risk of death and morbidity from stroke and coronary heart disease. There is accumulating evidence from large outcome studies that support a move towards lower treatment targets in hypertensives, particularly for those with concomitant risk factors or evidence of established target organ damage. At present, the achieved rates for BP control in the UK are very poor. Amongst the many possible reasons for poor BP control is the under utilisation of effective drug combinations. This article addresses the rationale for two and three drug combination therapy in hypertension and reviews the trial evidence for efficacy of combinations.

Keywords

hypertension treatment targets drug combinations third-line agents

Get full access to this article

View all access options for this article.

References

Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension II. Results in patients with diastolic blood pressure averaging 90 through 114 mmHg. JAMA 1970;213(7): 1143-52.

Blood Pressure Lowering Treatment Trialists ' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed clinical trials. Lancet 2000;355:1955-64.

Staessen JA , Wang J. -G, Thijs L. Cardiovascular protection and blood pressure reduction. Lancet 2001;358:1305-15.

Ramsey LE , Williams B. , Johnston GD et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999;319:630-5. (Available at www.hyp.ac.uk./bhs/management.html)

Joint National Committee on Prevention , Detection, Evaluation and Treatment of High Blood Pressure. The Sixth Report . Arch Intern Med 1997;157:2413-46. (Available at www.nhlbi.nih.gov/guidelines/index.html )

Chalmers J. , MacMahon S. , Mancia G. et al. 1999 World Health Organisation-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17:151-85. (Available at www.who.int/ncd/cvd/ht_guide.html)

Murray CJL , Lopez AD Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.

Primatesta P. , Brookes M. , Poulter NR

Improved hypertension management and control. Results from the Health Survey for England

1998. Hypertension 2001;38:827-32.

Marques-Vidal P. , Tuomilehto J.

Hypertension awareness, treatment and control in the community: is the `rule of halves' still valid?

J Hum Hypertens 1997;11(4):213-20.

10.

Hansson L. , Zanchetti A. , Carruthers SG et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62.

11.

Hansson L. , Lindholm LH , Ekbom T. et al., for the STOP-Hypertension-2 Study Group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6.

12.

Staessen JA , Fagard R. , Thijs L. et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated hypertension. Lancet 1997;350:757-64.

13.

Dahlöf B. , Devereux RB , Kjeldsen SE et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol . Lancet 2002;359: 995-1003.

14.

Bakris GL , Williams M. , Dworkin L. et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes:A consensus approach . Am J Kidney Dis 2000;36:646-61.

15.

Dickerson JEC , Hingorani AD , Ashby MJ , Palmer CR , Brown MJ Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.

16.

Materson BJ , Reda DJ , Cushman WC et al.,The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-Drug Therapy for Hypertension in Men -- A Comparison of Six Antihypertensive Agents with Placebo .NEnglJMed 1993;328:914-21.

17.

Mogensen CE , Neldam S. , Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.

18.

De Leeuw PW , Notter T. , Zilles P. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study . J Hypertens 1997; 15:87-91.

19.

Cappuccio FP , Markandu ND , Singer DRJ et al. A double-blind study of the concomitant diuretic therapy in hypertensive patients treated with amlodipine. Am J Hypertens 1991; 4:297-302.

20.

Salvetti A. , Magagna A. , Innocenti P. et al. Chlorthalidone does not increase the hypotensive effect of nifedipine in essential hypertensives in a crossover multicentre study. J Hypertens 1989;7(suppl 6):250-1.

21.

MacGregor GA , Markandu ND , Banks RA , Bayliss J. , Roulston JE , Jones JC Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propranolol . BMJ 1982;284(6317):693-6.

22.

Wing LM , Chalmers JP , West MJ et al. Treatment of hypertension with enalapril and hydrochlorothiazide or enalapril and atenolol: contrasts in hypotensive interactions. J Hypertens 1987;5(5):S603-06.

23.

Belz GG , Breithaupt K. , Erb K. , Kleinbloessem CH , Wolf GK Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta blocker propranolol and their combination on haemodynamics in hypertension . J Hypertens 1989;7:817-24.

24.

Sever PS , Dahlöf B. , Poulter NR et al., for the ASCOT investigators. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001;19:1139-47.

25.

MacGregor G. The St. George's `Star' and `Imploding Diamond' . J Hum Hypertens 1999;13:353-4.

26.

Isles CG , Walker LM , Beevers GD et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986;4(2): 141-56.

27.

McAreavey D. , Ramsey LE , Latham L. et al. `Third drug' trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic . BMJ 1984;288:106-19.

28.

Leonetti G. , Cuspidi C. , Sampieri L. et al. Evaluation of the efficacy and safety of enalapril plus hydrochlorothiazide plus methyldopa vs. standard triple therapy in the treatment of moderate to severe hypertension: results from a multicentre study. J Hum Hypertens 1990;4(1):5-11.

29.

Bevan EG , Pringle SD , Waller PC et al. Comparison of captopril, hydralazine and nifedipine as third drug in hypertensive patients. J Hum Hypertens 1993;7(1):83-8.

30.

Bevan EG , Pringle SD , Waller PC et al. Effects of atenolol withdrawal in patients on triple antihypertensive therapy. J Hum Hypertens 1993;7(1):89-93.

31.

Antonios TFT , Cappuccio FP , Markandu ND , Sagnella GA , MacGregor GA A diuretic is more effective than a β-blocker in hypertensive patients not controlled on amlodipine and lisinopril. Hypertension 1996;27:1325-8.

32.

Punzi HA , Novrit BA for the Trandolapril/Verapamil Multicentre Study Group.The treatment of severe hypertension with trandolapril, verapamil and hydrochlorothiazide . J Hum Hypertens 1997;11(8):477-81.

33.

MacGregor GA , Viskoper JR , Antonios TFT , He FJ , on behalf of the UK and Israel Candesartan Investigators. Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension . Hypertension 2000;36:454-60.

34.

Sacks FM , Svetkey LP , Vollmer WM et al., for the DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. N Engl J Med 2001;344(1):3-10.

35.

The ALLHAT Officers and Contributors for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).JAMA 2000;283(15):1967-75.

36.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342(3): 145-53.

37.

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.

38.

Björck S. , Mulek H. , Johnsen SA , Nordén G. , Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:330-43.

39.

Lewis EJ , Hunsicker LG , Clarke WM et al., for the Collaborative Study Group. Renoprotective effects of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

40.

Brenner BM , Cooper ME , de Zeeuw D. et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.